Tags

Type your tag names separated by a space and hit enter

Effect of the Pro12Ala polymorphism of the PPAR gamma 2 gene on response to pioglitazone treatment in menopausal women.
Menopause. 2008 Nov-Dec; 15(6):1151-6.M

Abstract

OBJECTIVE

To investigate the influence of the Pro12Ala polymorphism of the PPAR gamma 2 gene on metabolic and hormonal response to pioglitazone treatment in obese postmenopausal women.

DESIGN

We included 102 obese (body mass index [BMI] >or=30 kg/m2) and 97 nonobese (BMI <or=27 kg/m2) postmenopausal women. Anthropometric data were collected, and fasting glucose, insulin, leptin, follicle-stimulating hormone, luteinizing hormone, dehydroepiandrosterone, dehydroepiandrosterone sulfate, testosterone, estrone, estradiol, and adiponectin were measured and the PPAR gamma 2 Pro12Ala genotypes were determined. Eighty-three obese postmenopausal women were treated with pioglitazone 15 mg/day for 15 days, and hormone levels and insulin resistance (homeostasis model assessment of insulin resistance) were assessed before and after treatment.

RESULTS

Obese women had a higher BMI, waist-to-hip ratio, fasting glucose, insulin, homeostasis model assessment of insulin resistance, leptin, dehydroepiandrosterone, estradiol, testosterone, and adiponectin levels, whereas the follicle-stimulating hormone level was lower. Genotype frequencies were similar in obese and nonobese women. Analysis of the whole group showed that women with the Pro/Ala genotype had a higher BMI, waist-to-hip ratio, and fasting glucose (P < 0.04, P < 0.02, and P < 0.004, respectively) than the group with the Pro/Pro genotype. After pioglitazone treatment, glucose levels decreased in both genotypes, but at a greater amount in carriers of the Pro/Ala genotype (-15 mg/dL vs -7 mg/dL, P < 0.003). However, insulin and homeostasis model assessment of insulin resistance levels were lower in carriers of the Pro/Pro genotype (-4.0 vs 0.7 IU/L, P=0.009 and -1.0 vs -0.08, P = 0.03, respectively).

CONCLUSIONS

The Pro/Ala genotype of PPAR gamma 2 was associated with obesity and higher fasting glucose. Pioglitazone treatment in obese women with the Pro/Ala genotype induced a greater glucose decrease, and obese women may derive more benefit from this drug.

Authors+Show Affiliations

Instituto de Investigaciones Médicas, Universidad de Guanajuato, León Guanajuato, Mexico.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18551086

Citation

Ramírez-Salazar, Mónica, et al. "Effect of the Pro12Ala Polymorphism of the PPAR Gamma 2 Gene On Response to Pioglitazone Treatment in Menopausal Women." Menopause (New York, N.Y.), vol. 15, no. 6, 2008, pp. 1151-6.
Ramírez-Salazar M, Pérez-Luque E, Fajardo-Araujo M, et al. Effect of the Pro12Ala polymorphism of the PPAR gamma 2 gene on response to pioglitazone treatment in menopausal women. Menopause. 2008;15(6):1151-6.
Ramírez-Salazar, M., Pérez-Luque, E., Fajardo-Araujo, M., Garza, S. M., & Malacara, J. M. (2008). Effect of the Pro12Ala polymorphism of the PPAR gamma 2 gene on response to pioglitazone treatment in menopausal women. Menopause (New York, N.Y.), 15(6), 1151-6. https://doi.org/10.1097/gme.0b013e31816d5b2d
Ramírez-Salazar M, et al. Effect of the Pro12Ala Polymorphism of the PPAR Gamma 2 Gene On Response to Pioglitazone Treatment in Menopausal Women. Menopause. 2008 Nov-Dec;15(6):1151-6. PubMed PMID: 18551086.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of the Pro12Ala polymorphism of the PPAR gamma 2 gene on response to pioglitazone treatment in menopausal women. AU - Ramírez-Salazar,Mónica, AU - Pérez-Luque,Elva, AU - Fajardo-Araujo,Martha, AU - Garza,Sandra Martínez, AU - Malacara,Juan Manuel, PY - 2008/6/14/pubmed PY - 2009/4/2/medline PY - 2008/6/14/entrez SP - 1151 EP - 6 JF - Menopause (New York, N.Y.) JO - Menopause VL - 15 IS - 6 N2 - OBJECTIVE: To investigate the influence of the Pro12Ala polymorphism of the PPAR gamma 2 gene on metabolic and hormonal response to pioglitazone treatment in obese postmenopausal women. DESIGN: We included 102 obese (body mass index [BMI] >or=30 kg/m2) and 97 nonobese (BMI <or=27 kg/m2) postmenopausal women. Anthropometric data were collected, and fasting glucose, insulin, leptin, follicle-stimulating hormone, luteinizing hormone, dehydroepiandrosterone, dehydroepiandrosterone sulfate, testosterone, estrone, estradiol, and adiponectin were measured and the PPAR gamma 2 Pro12Ala genotypes were determined. Eighty-three obese postmenopausal women were treated with pioglitazone 15 mg/day for 15 days, and hormone levels and insulin resistance (homeostasis model assessment of insulin resistance) were assessed before and after treatment. RESULTS: Obese women had a higher BMI, waist-to-hip ratio, fasting glucose, insulin, homeostasis model assessment of insulin resistance, leptin, dehydroepiandrosterone, estradiol, testosterone, and adiponectin levels, whereas the follicle-stimulating hormone level was lower. Genotype frequencies were similar in obese and nonobese women. Analysis of the whole group showed that women with the Pro/Ala genotype had a higher BMI, waist-to-hip ratio, and fasting glucose (P < 0.04, P < 0.02, and P < 0.004, respectively) than the group with the Pro/Pro genotype. After pioglitazone treatment, glucose levels decreased in both genotypes, but at a greater amount in carriers of the Pro/Ala genotype (-15 mg/dL vs -7 mg/dL, P < 0.003). However, insulin and homeostasis model assessment of insulin resistance levels were lower in carriers of the Pro/Pro genotype (-4.0 vs 0.7 IU/L, P=0.009 and -1.0 vs -0.08, P = 0.03, respectively). CONCLUSIONS: The Pro/Ala genotype of PPAR gamma 2 was associated with obesity and higher fasting glucose. Pioglitazone treatment in obese women with the Pro/Ala genotype induced a greater glucose decrease, and obese women may derive more benefit from this drug. SN - 1530-0374 UR - https://www.unboundmedicine.com/medline/citation/18551086/Effect_of_the_Pro12Ala_polymorphism_of_the_PPAR_gamma_2_gene_on_response_to_pioglitazone_treatment_in_menopausal_women_ L2 - https://doi.org/10.1097/gme.0b013e31816d5b2d DB - PRIME DP - Unbound Medicine ER -